North America Injectable Drug Delivery Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024
The North America Injectable Drug Delivery Market is accounted to reach USD 354.53 billion by 2024 from USD 154.05 billion in 2016, at a CAGR of 5.4% in the forecast period 2017 to 2024.
The major factors driving the growth of this market are the prevalence of chronic diseases (such as cancer, diabetes, hormonal disorder, and many others), rapidly increasing aging population and the subsequent rise in chronic conditions, rising demand of self injection devices, technological advancement and innovations in drug delivery market. .
The key market players for North America Injectable Drug Delivery Devices Market are listed below:
Injectable drug delivery device market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases and other diseases on the basis of application
On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern.
On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system.
On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others.
Based on geography, the North America Injectable Drug Delivery Devices market is segmented into 11 geographical regions, such as,
The report covers the present scenario and the growth prospects of the North America Injectable Drug Delivery Devices market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
The major factors driving the growth of this market are the prevalence of chronic diseases (such as cancer, diabetes, hormonal disorder, and many others), rapidly increasing aging population and the subsequent rise in chronic conditions, rising demand of self injection devices, technological advancement and innovations in drug delivery market. .
The key market players for North America Injectable Drug Delivery Devices Market are listed below:
- Pfizer and Baxter International, Inc.,
- Gerresheimer AG,
- Schott AG, Alkermes Plc.,
- Eli Lilly and Company,
- Sandoz,
- Terumo Corporation,
- Teva Pharmaceuticals Industries Ltd.,
- Bespak, Antares Pharma,
- Elcam Medical,
- Haselmeier, Mylan N.V.,
- Novo Nordisk,
- Owen Mumford Ltd,Sanofi,
- West Pharmaceutical Services, Inc,
- Ypsomed Holding AG.
- Type
- Application
- Usage Pattern
- Mode Administration
- End User
- Geography
Injectable drug delivery device market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases and other diseases on the basis of application
On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern.
On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system.
On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others.
Based on geography, the North America Injectable Drug Delivery Devices market is segmented into 11 geographical regions, such as,
- U.S.,
- Canada,
- Mexico
The report covers the present scenario and the growth prospects of the North America Injectable Drug Delivery Devices market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
1 INTRODUCTION
1.1. OVERVIEW OF THE NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED
2 MARKET SEGMENTATION
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET TIME LINE
2.2.4 MARKET GUIDE
2.2.5 COMPANY POSITIONING GRID
2.2.6 COMAPANY MARKET SHARE ANALYSIS
2.2.7 MULTIVARIATE MODELLING
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 TOP TO BOTTOM ANALYSIS
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.4. ASSUMPTIONS
3 MARKET OVERVIEW
3.1. DRIVERS
3.2. RESTRAINTS
3.3. OPPORTUNITIES
3.4. CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1. VENDOR POSITIONING GRID AND INVESTMENT OPPORTUNITIES
5.2. TECHNOLOLGICAL ADVANCEMENTS
5.3. INSIGHTS ON TECHNOLOGICAL DEVELOPMENTS IN THE NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET
5.4. MARKET REGULATORY SCENARIO BY COUNTRY
5.5. INTERVIEW KEY INSIGHTS
6 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY TYPE
7 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
8 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, MODE ADMINISTRATION
9 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY END USER
10 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHY
11 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES
11.1 PFIZER AND BAXTER INTERNATIONAL, INC.
11.2 GERRESHEIMER AG
11.3 SCHOTT AG
11.4 ALKERMES PLC.
11.5 ELI LILLY AND COMPANY
11.6 COMPANY A
11.7 COMPANY B
11.8 COMPANY C
11.9 COMPANY D
11.10 COMPANY E
11.11 COMPANY F
11.12 COMPANY G
11.13 COMPANY H
11.14 COMPANY I
11.15 COMPANY J
11.16 COMPANY K
11.17 COMPANY M
11.18 COMPANY N
11.19 COMPANY O
12 APPENDIX
13 ABOUT DATA BRIDGE MARKET RESEARCH
1.1. OVERVIEW OF THE NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED
2 MARKET SEGMENTATION
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET TIME LINE
2.2.4 MARKET GUIDE
2.2.5 COMPANY POSITIONING GRID
2.2.6 COMAPANY MARKET SHARE ANALYSIS
2.2.7 MULTIVARIATE MODELLING
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 TOP TO BOTTOM ANALYSIS
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.4. ASSUMPTIONS
3 MARKET OVERVIEW
3.1. DRIVERS
3.2. RESTRAINTS
3.3. OPPORTUNITIES
3.4. CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1. VENDOR POSITIONING GRID AND INVESTMENT OPPORTUNITIES
5.2. TECHNOLOLGICAL ADVANCEMENTS
5.3. INSIGHTS ON TECHNOLOGICAL DEVELOPMENTS IN THE NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET
5.4. MARKET REGULATORY SCENARIO BY COUNTRY
5.5. INTERVIEW KEY INSIGHTS
6 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY TYPE
7 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
8 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, MODE ADMINISTRATION
9 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY END USER
10 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHY
11 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES
11.1 PFIZER AND BAXTER INTERNATIONAL, INC.
11.2 GERRESHEIMER AG
11.3 SCHOTT AG
11.4 ALKERMES PLC.
11.5 ELI LILLY AND COMPANY
11.6 COMPANY A
11.7 COMPANY B
11.8 COMPANY C
11.9 COMPANY D
11.10 COMPANY E
11.11 COMPANY F
11.12 COMPANY G
11.13 COMPANY H
11.14 COMPANY I
11.15 COMPANY J
11.16 COMPANY K
11.17 COMPANY M
11.18 COMPANY N
11.19 COMPANY O
12 APPENDIX
13 ABOUT DATA BRIDGE MARKET RESEARCH
